ST. LOUIS — All morning, nurses had been coming in, taking vitals, offering blankets, pressing buttons to silence alarms. It ...

THE United States has reaffirmed its commitment to supporting Tanzania in the fight against sickle cell disease with focus on ...

Sickle Cell Disease Market Size Was Valued at USD 2.40 Billion in 2023, and is Projected to Reach USD 12.38 Billion by 2032, ...

For all of its challenges, living with sickle cell has offered columnist Oluwatosin Adesoye resilience, empathy, support, and ...

As we commemorate the recent first anniversary of a renowned health journalist who was also a friend, Elizabeth Merab, we ...

The first two Sickle Cell Disease patients admitted to the Sickle Cell Foundation of Nigeria/Lagos University Teaching ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

About 36 Nigerians living abroad, are competing for a place on the eligibility list for the new bone marrow transplant ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

A patient with sickle cell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics, threatening to overshadow early signals of effective gene editing.

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.

According to Uganda's Ministry of Health, around 250,000 people in the country live with sickle cell disease, including an estimated 20,000 to 25,000 babies ...